Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets

Stock analysts at BMO Capital Markets assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Get Free Report) in a research report issued on Wednesday,Briefing.com Automated Import reports. The firm set an "outperform" rating and a $50.00 price target on the stock. BMO Capital Markets' price target suggests a potential upside of 315.63% from the stock's current price.

DYN has been the subject of a number of other reports. Robert W. Baird began coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an "outperform" rating and a $46.00 price objective for the company. Raymond James raised Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Scotiabank began coverage on Dyne Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $48.85.

Dyne Therapeutics Trading Up 4.6 %

Shares of DYN stock opened at $12.03 on Wednesday. The stock has a 50 day moving average of $15.33 and a 200 day moving average of $25.82. The stock has a market cap of $1.36 billion, a P/E ratio of -3.38 and a beta of 1.11. Dyne Therapeutics has a twelve month low of $11.18 and a twelve month high of $47.45.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. On average, research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DYN. State of New Jersey Common Pension Fund D purchased a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $1,588,000. Jennison Associates LLC increased its stake in Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company's stock valued at $48,383,000 after purchasing an additional 19,730 shares in the last quarter. abrdn plc purchased a new position in Dyne Therapeutics in the 4th quarter valued at approximately $608,000. RA Capital Management L.P. increased its stake in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company's stock valued at $66,802,000 after purchasing an additional 84,760 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.